{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:39:44Z","timestamp":1792528784999,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015544","name":"King's College Hospital Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics &amp; Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejogrb.2026.115321","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:23:38Z","timestamp":1784647418000},"page":"115321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis"],"prefix":"10.1016","volume":"325","author":[{"given":"R.","family":"Mohamed-Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rantell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejogrb.2026.115321_b0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"21","author":"Haylen","year":"2010","journal-title":"Int Urogynecol J"},{"issue":"7","key":"10.1016\/j.ejogrb.2026.115321_b0010","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115321_b0015","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115321_b0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115321_b0025","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115321_b0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115321_b0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1756287215614237","article-title":"The efficacy and tolerability of mirabegron, a \u03b23 adrenoceptor agonist, in patients with symptoms of overactive bladder","volume":"8","author":"Thiagamoorthy","year":"2016","journal-title":"Ther Adv Urol"},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115321_b0040","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","article-title":"Vibegron, a novel potent and selective \u03b2(3)-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Yoshida","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejogrb.2026.115321_b0045","unstructured":"Excellence NIfHaC. Vibegron for treating symptoms of overactive bladder syndrome. TA999. 2024."},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115321_b0050","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JU.0000000000000807","article-title":"International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR","volume":"204","author":"Staskin","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.ejogrb.2026.115321_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ejogrb.2026.115321_b0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejogrb.2026.115321_b0065","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ejogrb.2026.115321_b0070","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jrsm.1373","article-title":"MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta","volume":"10","author":"Owen","year":"2019","journal-title":"Res Synth Methods"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115321_b0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejogrb.2026.115321_b0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jclinepi.2023.02.016","article-title":"A multifaceted graphical display, including treatment ranking, was developed to aid interpretation of network meta-analysis","volume":"157","author":"Nevill","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.ejogrb.2026.115321_b0085","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/nau.22645","article-title":"Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder in Asia","volume":"34","author":"Kuo","year":"2015","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115321_b0090","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ejogrb.2026.115321_b0095","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomised, double-blind, placebo-controlled study of the \u03b23-adrenoceptor agonist mirabegron, 50\u2009mg once daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115321_b0100","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/JU.0000000000001574","article-title":"Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International phase 3 Trial (EMPOWUR)","volume":"205","author":"Staskin","year":"2021","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115321_b0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/luts.12475","article-title":"Efficacy and safety of vibegron compared with mirabegron for overactive bladder: a systematic review and network meta-analysis","volume":"15","author":"He","year":"2023","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.ejogrb.2026.115321_b0110","article-title":"Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis","volume":"11","author":"Kennelly","year":"2022","journal-title":"Drugs Context"},{"issue":"4","key":"10.1016\/j.ejogrb.2026.115321_b0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/luts.12480","article-title":"Mirabegron versus vibegron in previously untreated female patients with overactive bladder: a randomized, single-clinic, open-label trial","volume":"15","author":"Sato","year":"2023","journal-title":"Low Urin Tract Symptoms"},{"issue":"11","key":"10.1016\/j.ejogrb.2026.115321_b0120","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/14740338.2017.1376646","article-title":"Safety issues associated with using medication to treat overactive bladder","volume":"16","author":"Araklitis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115321_b0125","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2017.01.037","article-title":"Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in patients with Overactive Bladder: a Retrospective Observational Study in UK Clinical Practice","volume":"72","author":"Chapple","year":"2017","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.ejogrb.2026.115321_b0130","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/nau.25478","article-title":"Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: a retrospective claims study","volume":"43","author":"Chastek","year":"2024","journal-title":"Neurourol Urodyn"}],"container-title":["European Journal of Obstetrics &amp; Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211526003891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211526003891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:04:42Z","timestamp":1792526682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211526003891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S0301211526003891"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2026.115321","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2026.115321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115321"}}